1. Home
  2. CCHH vs INAB Comparison

CCHH vs INAB Comparison

Compare CCHH & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CCHH

CCH Holdings Ltd Ordinary Shares

N/A

Current Price

$0.51

Market Cap

10.2M

Sector

N/A

ML Signal

N/A

Logo IN8bio Inc.

INAB

IN8bio Inc.

HOLD

Current Price

$2.36

Market Cap

10.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CCHH
INAB
Founded
2015
2016
Country
Malaysia
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.2M
10.6M
IPO Year
2025
2021

Fundamental Metrics

Financial Performance
Metric
CCHH
INAB
Price
$0.51
$2.36
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$108.00
AVG Volume (30 Days)
2.0M
686.5K
Earning Date
02-08-2026
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.01
N/A
Revenue
$9,138,264.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$40.58
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.49
$1.17
52 Week High
$15.39
$12.53

Technical Indicators

Market Signals
Indicator
CCHH
INAB
Relative Strength Index (RSI) N/A 65.76
Support Level N/A $1.17
Resistance Level N/A $2.24
Average True Range (ATR) 0.00 0.24
MACD 0.00 0.10
Stochastic Oscillator 0.00 98.54

Price Performance

Historical Comparison
CCHH
INAB

About CCHH CCH Holdings Ltd Ordinary Shares

CCH Holdings Ltd operates a hotpot restaurant chain in Malaysia, specializing in chicken hotpot and fish head hotpot, mainly under two brand, namely Chicken Claypot House and Zi Wei Yuan, owned by the wholly owned subsidiaries of the Company. The Company conducts its operations through its wholly owned subsidiaries in Malaysia and is engaged as a restaurant operator, licensor and loyalty owner, and general trader. Currently, the Group has developed a restaurant chain including approximately 15 company-owned restaurant outlets, 13 franchised restaurant outlets in Malaysia, and 4 franchised restaurant outlets outside Malaysia.

About INAB IN8bio Inc.

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.

Share on Social Networks: